Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will engage in a fireside chat during the virtual event on February 12, 2025, at 1:20 pm ET.
Interested parties can access the webcast through a direct link or via the 'Events and Presentations' section of Fulcrum's investor relations website. The presentation recording will remain available for a minimum of 30 days following the event on the company's website.
Fulcrum Therapeutics (Nasdaq: FULC), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di piccole molecole per malattie genetiche rare, ha annunciato la sua prossima partecipazione alla 35a Conferenza Annuale sulle Scienze della Vita di Oppenheimer. Il management dell'azienda parteciperà a una chiacchierata informale durante l'evento virtuale il 12 febbraio 2025, alle 13:20 ET.
Le parti interessate possono accedere al webcast tramite un link diretto o attraverso la sezione 'Eventi e Presentazioni' del sito web delle relazioni con gli investitori di Fulcrum. La registrazione della presentazione rimarrà disponibile per un minimo di 30 giorni dopo l'evento sul sito web dell'azienda.
Fulcrum Therapeutics (Nasdaq: FULC), una empresa biofarmacéutica en etapa clínica especializada en el desarrollo de pequeñas moléculas para enfermedades genéticas raras, ha anunciado su próxima participación en la 35ª Conferencia Anual sobre Ciencias de la Salud de Oppenheimer. La dirección de la empresa participará en una conversación informal durante el evento virtual el 12 de febrero de 2025, a la 1:20 p. m. ET.
Las partes interesadas pueden acceder a la transmisión a través de un enlace directo o mediante la sección 'Eventos y Presentaciones' en el sitio web de relaciones con inversores de Fulcrum. La grabación de la presentación estará disponible durante un mínimo de 30 días después del evento en el sitio web de la empresa.
Fulcrum Therapeutics (Nasdaq: FULC)는 희귀 유전 질환을 위한 소분자 개발을 전문으로 하는 임상 단계의 생명공학 회사로, Oppenheimer 제35회 연례 헬스케어 생명과학 컨퍼런스에 참여할 예정이라고 발표했습니다. 회사 경영진은 2025년 2월 12일 오후 1시 20분 ET에 열리는 가상 이벤트에서 불꽃놀이 대화에 참여할 것입니다.
관심 있는 당사자는 Fulcrum의 투자자 관계 웹사이트의 '이벤트 및 발표' 섹션 또는 직접 링크를 통해 웹캐스트에 접속할 수 있습니다. 발표 녹화는 이벤트 이후 최소 30일 동안 회사 웹사이트에서 이용 가능할 것입니다.
Fulcrum Therapeutics (Nasdaq: FULC), une entreprise bio-pharmaceutique en phase clinique spécialisée dans le développement de petites molécules pour des maladies génétiques rares, a annoncé sa prochaine participation à la 35e Conférence Annuelle sur les Sciences de la Vie d'Oppenheimer. La direction de l'entreprise participera à une discussion informelle lors de l'événement virtuel le 12 février 2025 à 13h20 ET.
Les parties intéressées peuvent accéder au webinaire via un lien direct ou par le biais de la section 'Événements et Présentations' du site Web des relations investisseurs de Fulcrum. L'enregistrement de la présentation restera disponible pendant au moins 30 jours après l'événement sur le site Web de l'entreprise.
Fulcrum Therapeutics (Nasdaq: FULC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von kleinen Molekülen für seltene genetische Erkrankungen spezialisiert hat, hat seine bevorstehende Teilnahme an der 35. jährlichen Oppenheimer Healthcare Life Sciences Conference bekannt gegeben. Das Management des Unternehmens wird am 12. Februar 2025 um 13:20 Uhr ET an einem informellen Gespräch während der virtuellen Veranstaltung teilnehmen.
Interessierte Parteien können über einen direkten Link oder über den Abschnitt 'Veranstaltungen und Präsentationen' auf der Investor-Relations-Website von Fulcrum auf den Webcast zugreifen. Die Aufzeichnung der Präsentation wird mindestens 30 Tage nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 at 1:20 pm ET.
The webcast of the fireside chat will be accessible HERE and by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead program in clinical development is pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
FAQ
When is Fulcrum Therapeutics (FULC) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors access FULC's Oppenheimer Conference presentation?
How long will FULC's Oppenheimer Conference presentation be available for replay?
What is the format of FULC's participation in the Oppenheimer Healthcare Conference 2025?
Is the Oppenheimer Healthcare Conference 2025 featuring FULC an in-person or virtual event?
